Eli Lilly and Company has withdrawn its supplemental New Drug Application from the U.S. FDA for Cymbalta (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.
The details can be read here.
No comments:
Post a Comment